Recombinant Anti-CD19 x Anti-CD22 Bispecific Antibody (scFv-IgG) (BSSG-039)

Recombinant Anti-CD19 x Anti-CD22 Bispecific Antibody (scFv-IgG) is formed by an IgG and two scFv fragments. The scFvs from an anti-CD19 antibody variable domain are respectively connected to the N terminus of the anti-CD22 IgG heavy chains or light chains to form scFv-(H)IgG or scFv-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb is designed for the research of B cell lymphoma; Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

CD19 & CD22

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD22

Gene ID

933

UniProt ID

P20273

Alternative Names

CD22; CD22 molecule; Cluster of differentiation 22; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD19 x Anti-CD22 Bispecific Antibody (scFv-IgG) (BSSG-039). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD19 x Anti-CD22 Bispecific Antibody (scFv-IgG) (CAT#: BSSG-039)

Specifications

Targets

Customer Reviews and Q&As